Avis et décisions de la HAS
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
Voir aussi
Avis et décisions de la HAS
17/11/2017
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
Xp19Rs0YMee2tdup